- ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
- ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
- ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
- ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
- ADMA Biologics Announces CFO Transition
- ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
- ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
- ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
More ▼
Key statistics
As of last trade ADMA Biologics Inc (ADMA:NMQ) traded at 11.44, -2.10% below its 52-week high of 11.68, set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.21 |
---|---|
High | 11.45 |
Low | 11.01 |
Bid | 11.43 |
Offer | 11.44 |
Previous close | 11.21 |
Average volume | 3.32m |
---|---|
Shares outstanding | 231.81m |
Free float | 217.24m |
P/E (TTM) | -- |
Market cap | 2.60bn USD |
EPS (TTM) | -0.0204 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:29 BST.
More ▼